Results 241 to 250 of about 139,183 (310)

The first case of paraneoplastic pemphigus positive for IgG autoantibodies against integrin α6. [PDF]

An Bras Dermatol
Li Y, Dong Y, Zeng X, Li W, Zhou Y, Li X.   +5 more
europepmc   +1 more source

NETosis: A bridge between cancer and autoimmunity

Rheumatology &Autoimmunity, EarlyView.
Niloufar Orooji, Manouchehr Fadaee
wiley   +1 more source

Autoimmune Processes and Chronic Inflammation as Independent Risk Factors for Metabolic Complications in Women with Polycystic Ovary Syndrome. [PDF]

Metabolites
Suchta K, Zeber-Lubecka N, Grymowicz M, Smolarczyk R, Kulecka M, Hennig EE.   +5 more
europepmc   +1 more source

Autoantibodies in COVID-19: implications for disease severity and clinical outcomes. [PDF]

Front Immunol
Galipeau Y, Cooper C, Langlois MA.
europepmc   +1 more source

A case of visceral leishmaniasis mimicking connective tissue disease

Rheumatology &Autoimmunity, EarlyView.
Yucui Li, Hongxia Yang, Tingzi Zhao, Ke Xu, Liyun Zhang   +4 more
wiley   +1 more source

Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires

The Journal of Dermatology, EarlyView.
Abstract Patients with autoimmune bullous disease have their quality of life (QOL) affected by both the disease and its treatment burden. While QOL assessment is clinically important, it is often hindered by limited time in clinical practice, highlighting the need for accurate and efficient QOL evaluation tools. However, no validated QOL questionnaires
Chika Tanemura, Maya Nunotani, Kyoko Kawabata, Yuki Morooka, Jun Yamagami, Risa Kakuta, Yasuko Saito, Yuichi Kurihara, Hayato Takahashi, Norito Ishii, Hiroshi Koga, Takekuni Nakama, Daisuke Hayashi, Sho Hiroyasu, Chiharu Tateishi, Daisuke Tsuruta, Dedee F. Murrell, Takashi Hashimoto   +17 more
wiley   +1 more source

Microarray-Based Avidity Assay for Assessment of Thyroid Autoantibodies. [PDF]

Diagnostics (Basel)
Savvateeva E, Sokolova V, Yukina M, Nuralieva N, Kulagina E, Donnikov M, Kovalenko L, Kazakova M, Troshina E, Gryadunov D.   +9 more
europepmc   +1 more source

Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease worldwide. In the difficult‐to‐treat BP or if standard therapies are contraindicated, the use of biologics may be also considered although there is no strong evidence supporting their use.
Gianluca Avallone, Carlo Alberto Maronese, Martina Zussino, Simona Muratori, Silvia Mariel Ferrucci, Pietro Quaglino, Elisabetta Manni, Marco Romanelli, Clara De Simone, Caterina Foti, Luigi Gargiulo, Vincenzo Maione, Piergiacomo Calzavara‐Pinton, Federico Bardazzi, Bianca Maria Piraccini, Emiliano Antiga, Giulia Rech, Riccardo Balestri, Pamela Vezzoli, Paolo Sena, Maria Esposito, Maria Concetta Fargnoli, Davide Termini, Luca Valtellini, Rosanna Rita Satta, Camilla Vassallo, Alessia Provini, Giovanni Di Zenzo, Anna Campanati, Marzia Caproni, Emanuele Cozzani, Simone Ribero, Angelo Valerio Marzano, DUO—DUpilumab and Omalizumab in Bullous Pemphigoid Study Group, Armando Pisapia, Giovanni Genovese, Federica Gelato, Luca Mastorino, Cristian Fidanzi, Luca Rapparini, Domenico Simeoli, Elena Marra, Gennaro Marco Falco, Paolo Romita, Riccardo Viola, Mauro Grandolfo, Luciano Ibba, Luisa Sarno, Roberto Maglie, Valentina Ruffo di Calabria, Aurora Parodi   +50 more
wiley   +1 more source

Investigation of new autoantibodies in urothelial bladder cancer for biomarker discovery using immunoproteomics. [PDF]

Discov Oncol
Tabaei S, Zareinejad M, Haghshenas MR, Shakhssalim N, Gilany K, Stensballe A, Ghaderi A.   +6 more
europepmc   +1 more source

Pemphigoid disease model systems for clinical translation. [PDF]

Front Immunol
Tigges M, Dräger S, Piccini I, Bieber K, Vorobyev A, Edelkamp J, Bertolini M, Ludwig RJ.   +7 more
europepmc   +1 more source